Cardionyx Heart Science

Company Overview

Snapshot

Founded in November 2020, Cardionyx Heart Science operates with 1–10 employees. The company has raised $700K across one funding round. In August 2023, Cardionyx Heart Science secured its initial funding.

Business overview

Cardionyx Heart Science is at the forefront of medical innovation, developing an active implant designed to stimulate baroreceptors for Heart Failure (HF) patients with reduced ejection fraction (HFrEF). The core technology involves a trans-vessel active implant that leverages venous catheterization for a minimally invasive procedure. This implant provides personalized therapy through real-time hemodynamic monitoring, allowing for dynamic regulation of parasympathetic tone. The company serves the healthcare industry, focusing on chronic patients and healthcare providers, and operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Company Intelligence Q&A

What is Cardionyx Heart Science's primary focus?

Cardionyx Heart Science is developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, utilizing a minimally invasive approach.

When was Cardionyx Heart Science founded?

Cardionyx Heart Science was founded in November 2020.

What is the key innovation of Cardionyx Heart Science's technology?

The company's key innovation is a first-of-its-kind trans-vessel active implant that enables personalized therapy with real-time hemodynamic monitoring for dynamic regulation of parasympathetic tone.

What is the total capital raised by Cardionyx Heart Science?

Cardionyx Heart Science has raised a total of $700K.

Which sectors does Cardionyx Heart Science operate in?

Cardionyx Heart Science operates in the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics.